NKGen Biotech Inc (NASDAQ:NKGN) shares traded higher on Monday, with a strong session volume of 19.25 million, compared to an average 100-day volume of 2.85 million, according to data from Benzinga Pro. However, there is no news to justify the +20% increase in the stock price. NKGen Biotech will present details about its NK cell therapy for neurodegenerative disease, review its preclinical data for Parkinson’s disease, and highlight clinical safety and efficacy data from the recently completed P